← Back to Clinical Trials
Recruiting NCT02282969

NCT02282969 PCORI-CER-1306-03385 Lung Cancer Screening Decision Aid Development and Testing

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT02282969
Status Recruiting
Phase
Sponsor M.D. Anderson Cancer Center
Condition Health Knowledge, Attitudes, Practice
Study Type OBSERVATIONAL
Enrollment 620 participants
Start Date 2014-07-11
Primary Completion 2028-08-31

Eligibility & Interventions

Sex All sexes
Min Age 55 Years
Max Age 80 Years
Study Type OBSERVATIONAL
Interventions
InterviewsQuestionnaires

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 620 participants in total. It began in 2014-07-11 with a primary completion date of 2028-08-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Objectives: This protocol addresses the first phase of a larger project funded by the Patient-Centered Outcomes Research Institute to help heavy smokers make informed decisions about lung cancer screening with low-dose computed tomography (CT). A separate IRB protocol will be submitted for the larger, comparative study. In this initial development phase, our prototype patient decision aid will be updated to reflect current guidelines about lung cancer screening. The updated aid will then be pilot-tested in a new sample of patients. In addition, several of the study measures will be refined and further developed in preparation for the larger study. The specific aims of the measures and decision aid development phase of this project are as follows: Update the aid to reflect current screening guidelines and refine the aid via cognitive testing with patients/smokers; and pilot test the updated aid for acceptability with patients/smokers. Modify our current measure of lung cancer knowledge, conduct cognitive testing of the new measure with patients/smokers, and evaluate the reliability of the new measure in a sample patients/smokers.

Eligibility Criteria

Inclusion Criteria: 1. Men and women 55 to 80 years of age. 2. Participants must speak English. 3. Current smoker or quit smoking within the past 15 years. Exclusion Criteria: 1\. History of lung cancer.

Contact & Investigator

Central Contact

Robert Volk, PHD

✉ BVolk@mdanderson.org

📞 713-563-2509

Principal Investigator

Robert Volk, PHD

STUDY CHAIR

M.D. Anderson Cancer Center

Frequently Asked Questions

Who can join the NCT02282969 clinical trial?

This trial is open to participants of all sexes, aged 55 Years or older, up to 80 Years, studying Health Knowledge, Attitudes, Practice. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT02282969 currently recruiting?

Yes, NCT02282969 is actively recruiting participants. Contact the research team at BVolk@mdanderson.org for enrollment information.

Where is the NCT02282969 trial being conducted?

This trial is being conducted at Galveston, United States, Houston, United States.

Who is sponsoring the NCT02282969 clinical trial?

NCT02282969 is sponsored by M.D. Anderson Cancer Center. The principal investigator is Robert Volk, PHD at M.D. Anderson Cancer Center. The trial plans to enroll 620 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology